Next Phase Newsletter

A firm actively funds, supports and advances life science technologies from early development through clinical proof-of-concept. The firm’s experienced leadership team works with scientists and entrepreneurs to provide active mentorship, financing solutions and operational guidance to increase the probability of success in early drug development. The firm has access to capital to support companies from seed investment through Series A and B financings and the size of initial seed investment can range from $0.5M to $1.5M. The subsequent Series A investments will be sized to get through preclinical and IND-enabling work and/or through a clinical development study and can range between $8M-$20M, with flexibility to syndicate with investors for larger rounds. For more mature companies that don’t require a seed round or the need to do complete activities/studies prior to a Series A, the firm can invest directly as a Series A investment along with participation in related Series B investments. The firm is open to global opportunities.

The firm supports opportunities across all therapeutic areas and drug modalities (small molecule, peptides, antibodies, genetic technologies, cell therapy, etc.).  Additionally, the firm is open to technologies beyond drug therapeutics, including medical devices, diagnostics and emerging healthtech opportunities (digital health, telemedicine, enabling technologies utilizing AI/ML, etc.). Founder and entrepreneur friendly and supportive of first-time CEOs, the firm works side by side to drive value inflections with the goal to optimize program development and successful outcomes.

The firm is open to working with all types of management teams, including first time entrepreneurs. The firm works hands-on with its portfolio companies by bringing a powerful network, access to resources and expertise to support their growth. The firm prefers to lead but is open to participating with likeminded co-investors to form syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based firm invests the capital of a small cohort of high-net-worth individuals.  The fund makes growth-stage investments in the healthcare sector, with a highly varied rate and size of allocations. The firm is interested in investment opportunities in North America, Europe and the Middle East.

The firm primarily invests in healthcare services and avoids opportunities that involve scientific or regulatory risk.  The fund is interested in approved medical devices and healthcare supplier/engineering companies that have products on the market; healthcare IT, and connected devices/connected hospital hardware are particularly of interest. The firm does not invest in drug development or biotech R&D companies.

The firm only invests in companies with revenues and indications of market adoption; the fund has no lower bar for revenue rates but will not fund initial batches of a product, as the firm requires data on market receptivity.  The fund invests with a 5-10 year horizon and is therefore interested in long-term growth opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital and growth equity firm is actively making investments in life sciences, and will invest as early as Series A and through growth transactions and is currently investing out of their second fund. New Rhein looks to invest between $10-30M per investment. The firm is looking for companies with clinical data and/or commercial products. The firm has a preference for funding companies that are repurposing existing approved technologies for new indications. The firm is willing to invest in therapeutics, medical device and diagnostics companies.

The firm has a primary focus on pharmaceuticals / therapeutics, and a secondary focus on medical devices. The firm is agnostic to indication.

The firm plays an active role in their portfolio companies. The firm will take a board seat with any company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global leader in life sciences, diagnostics and applied chemical markets providing services, equipment, and support solutions to laboratories worldwide has an Early Stage Partnership Program through which the firm works with, and potentially invests in, early proof-of-concept to revenue stage companies that are a strategic fit to the firm’s core products and services. Apart from financial investing, the firm provides strategic support to the companies with whom they partner. While the firm will partner globally, it has primarily partnered with US and European companies to this point.

The firm partners with early stage companies that provide game-changing tools, technologies and applications to advance the Life Science Research, Clinical Research and Diagnostic markets. Within these markets, the firm is especially interested in the fields of Bioproduction Instrumentation, Cell & Gene Therapy Tools, Cellular Engineering and Analysis, Genomics, Lab Data Analytics & Informatics, Molecular Diagnostics and Sample Preparation. The firm is currently not considering therapeutics or medical devices. The firm has partnered with companies early in proof of concept and up to revenue-generating companies.

The firm’s Early Stage Partnership program will only invest in companies that are a strategic fit, but operates as a financial investor, separating any strategic partnerships from the financial investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with multiple offices in the USA has assets under management of $1.6 billion. Since inception, the firm has raised five investment funds. The firm typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $20 million throughout a portfolio company’s path to liquidity.

The firm is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has invested in biopharmaceutical companies focused on developing drugs to treat enteral feeding intolerance and disorders that are driven by CD47-mediated signaling pathways, including leukemia, lymphoma, solid tumors, and pulmonary hypertension. In addition, the firm has invested in a medical device developing a minimally-invasive, catheter-based device to re-create valves in deep leg veins. The firm does not look at diagnostics, though may be interested in technology with real-time feedback for procedures.

The firm focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the firm is able to help entrepreneurs achieve near-term objectives that position their companies for exit.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based out of USA that invests exclusively in the mental health and neurology space. The firm’s biotech segment is interested in companies related to neuroscience and neurotherapeutics. The firm is raising their second fund right now, their first fund closed at over $22M. The firm looks to make Seed and Series A investments in the form of equity or convertible notes with a typical check size ranging from $500K-1.5M. The firm seeks to make investments in North America and Europe.

The firm is open to all 4 sectors as they relate to neurology. The firm is agnostic to subsector and indication with a particular focus on psychiatry and neurodegenerative diseases. The firm is open to pre-clinical and pre-prototype companies and is open to all 3 classes of medical devices with a stronger focus on 510K and PMA.

The firm is open to all types of management teams and is willing to lead or co-invest and will seek a board seat when leading.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A fully integrated healthcare solution provider headquartered in China is leading in several market segments in Asia, including family planning medicines, anesthesia, medicines for central nervous system, bio-medicines and others. The group is seeking in-licensing, acquisition, and partnership opportunities based in China and North America. For early stage assets, allocation sizes can be flexible, ranging from $2-10M per deal. The group can either lead or co-invest in a financing round. The firm prefers companies with a China angle and seeks distribution rights in the Chinese market; however this is not a prerequisite criterion.

The firm considers a wide range of technology sectors including therapeutics, medical devices, diagnostics, and healthcare IT. In therapeutics, the group is interested in small molecules, biologics, cell and gene therapies, and biosimilars for oncology, women’s health, CNS, pain management, and infectious diseases. The group seeks assets from preclinical stage to proof-of-concept phase 1. In medical devices, the firm prefers 510K and low-risk devices.

The firm is looking for companies with a complete management team formed by devoted and trustworthy members with domain expertise. The group typically seeks board representation after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.